Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-ALS: Deferiprone in Amyotrophic Lateral Sclerosis
NCT02164253Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Sep 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in amyotrophic lateral sclerosis (ALS), sponsored by CHU de Lille. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale. Started Sep 2013; status: completed.
02
Drugs
deferiprone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02164253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164253.